Patents by Inventor JOHN Harrison THORNLEY

JOHN Harrison THORNLEY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210085870
    Abstract: In example methods and systems described, insulin therapy for a patient can be determined. At least one of a short-acting subcutaneous insulin dosage recommendation, a correction subcutaneous insulin dosage recommendation, an intravenous insulin dosage recommendation, a recommended amount of carbohydrates to be administered to the patient, or combinations thereof, can be determined. In addition, information indicating a confirmation of a nutrition intake for the patient, and a long-acting insulin-on-board for the patient can be received, and based on this information, a required long-acting subcutaneous or intravenous insulin dosage for the patient can be determined. The short-acting subcutaneous or intravenous insulin dosage recommendation can be adjusted based, at least in part, on a difference between the long-acting insulin-on-board and the required long-acting subcutaneous or intravenous insulin dosage.
    Type: Application
    Filed: November 20, 2020
    Publication date: March 25, 2021
    Applicant: MONARCH MEDICAL TECHNOLOGIES, LLC
    Inventors: TIMOTHY L. RUCHTI, WILLIAM PATRICK BURGESS, JOHN DUMAS, III, RONALD LISIECKI, CAROL DIAN MARTIN, LAURA SANTANA, JOHN HARRISON THORNLEY, JOANNE MARIE WATT
  • Patent number: 10842935
    Abstract: In example methods and systems described, insulin therapy for a patient can be determined. At least one of a short-acting subcutaneous insulin dosage recommendation, a correction subcutaneous insulin dosage recommendation, an intravenous insulin dosage recommendation, a recommended amount of carbohydrates to be administered to the patient, or combinations thereof, can be determined. In addition, information indicating a confirmation of a nutrition intake for the patient, and a long-acting insulin-on-board for the patient can be received, and based on this information, a required long-acting subcutaneous or intravenous insulin dosage for the patient can be determined. The short-acting subcutaneous or intravenous insulin dosage recommendation can be adjusted based, at least in part, on a difference between the long-acting insulin-on-board and the required long-acting subcutaneous or intravenous insulin dosage.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: November 24, 2020
    Assignee: Monarch Medical Technologies, LLC
    Inventors: Timothy L. Ruchti, William Patrick Burgess, John Dumas, III, Ronald Lisiecki, Carol Dian Martin, Laura Santana, John Harrison Thornley, Joanne Marie Watt
  • Publication number: 20180333535
    Abstract: In example methods and systems described, insulin therapy for a patient can be determined. At least one of a short-acting subcutaneous insulin dosage recommendation, a correction subcutaneous insulin dosage recommendation, an intravenous insulin dosage recommendation, a recommended amount of carbohydrates to be administered to the patient, or combinations thereof, can be determined. In addition, information indicating a confirmation of a nutrition intake for the patient, and a long-acting insulin-on-board for the patient can be received, and based on this information, a required long-acting subcutaneous or intravenous insulin dosage for the patient can be determined. The short-acting subcutaneous or intravenous insulin dosage recommendation can be adjusted based, at least in part, on a difference between the long-acting insulin-on-board and the required long-acting subcutaneous or intravenous insulin dosage.
    Type: Application
    Filed: July 30, 2018
    Publication date: November 22, 2018
    Applicant: Monarch Medical Technologies, LLC
    Inventors: Timothy L. Ruchti, William Patrick Burgess, John Dumas, III, Ronald Lisiecki, Carol Dian Martin, Laura Santana, John Harrison Thornley, Joanne Marie Watt
  • Patent number: 10046113
    Abstract: In example methods and systems described, insulin therapy for a patient can be determined. At least one of a short-acting subcutaneous insulin dosage recommendation, a correction subcutaneous insulin dosage recommendation, an intravenous insulin dosage recommendation, a recommended amount of carbohydrates to be administered to the patient, or combinations thereof, can be determined. In addition, information indicating a confirmation of a nutrition intake for the patient, and a long-acting insulin-on-board for the patient can be received, and based on this information, a required long-acting subcutaneous or intravenous insulin dosage for the patient can be determined. The short-acting subcutaneous or intravenous insulin dosage recommendation can be adjusted based, at least in part, on a difference between the long-acting insulin-on-board and the required long-acting subcutaneous or intravenous insulin dosage.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: August 14, 2018
    Assignee: Monarch Medical Technologies, LLC
    Inventors: Timothy L. Ruchti, William Patrick Burgess, John Dumas, III, Ronald Lisiecki, Carol Dian Martin, Laura Santana, John Harrison Thornley, Joanne Marie Watt
  • Publication number: 20170165425
    Abstract: In example methods and systems described, insulin therapy for a patient can be determined. At least one of a short-acting subcutaneous insulin dosage recommendation, a correction subcutaneous insulin dosage recommendation, an intravenous insulin dosage recommendation, a recommended amount of carbohydrates to be administered to the patient, or combinations thereof, can be determined. In addition, information indicating a confirmation of a nutrition intake for the patient, and a long-acting insulin-on-board for the patient can be received, and based on this information, a required long-acting subcutaneous or intravenous insulin dosage for the patient can be determined. The short-acting subcutaneous or intravenous insulin dosage recommendation can be adjusted based, at least in part, on a difference between the long-acting insulin-on-board and the required long-acting subcutaneous or intravenous insulin dosage.
    Type: Application
    Filed: December 21, 2012
    Publication date: June 15, 2017
    Applicant: EndoTool, LLC
    Inventors: Timothy L. Ruchti, William Patrick Burgess, John Dumas, III, Ronald Lisiecki, Carol Dian Martin, Laura Santana, John Harrison Thornley, Joanne Marie Watt
  • Patent number: 8771251
    Abstract: In example methods and systems described, a medical device can store information locally and in a separate database on a server, for example. If the device fails, or a patient is moved to a second device, information may be transferred to the second device such that the second device can resume a complex therapy at a point where the initial medical device left off. The data necessary to restart the complex therapy system may include certain underlying patient-specific parameters according to a model capturing the patient's physiological response to the medication in question. As a result, it is not necessary for the second device to restart the complex therapy or regress to an initial set of baseline assumptions.
    Type: Grant
    Filed: December 16, 2010
    Date of Patent: July 8, 2014
    Assignee: Hospira, Inc.
    Inventors: Timothy Lewis Ruchti, Steven R. Wehba, John Harrison Thornley, Harsh Dharwad, Joanne Marie Watt, Carol Dian Martin, Suzanne Willey
  • Publication number: 20110152830
    Abstract: In example methods and systems described, a medical device can store information locally and in a separate database on a server, for example. If the device fails, or a patient is moved to a second device, information may be transferred to the second device such that the second device can resume a complex therapy at a point where the initial medical device left off. The data necessary to restart the complex therapy system may include certain underlying patient-specific parameters according to a model capturing the patient's physiological response to the medication in question. As a result, it is not necessary for the second device to restart the complex therapy or regress to an initial set of baseline assumptions.
    Type: Application
    Filed: December 16, 2010
    Publication date: June 23, 2011
    Applicant: HOSPIRA, INC.
    Inventors: TIMOTHY L. RUCHTI, STEVEN R. WEHBA, JOHN Harrison THORNLEY, HARSH DHARWAD, JOANNE Marie WATT, CAROL Dian MARTIN, SUZANNE WILLEY